Related Experiment Videos
[Sulbactam/ampicillin-induced pneumonitis]
N Miyashita1, M Nakajima, M Kuroki
1Department of Medicine, Kawasaki Medical School, Okayama, Japan.
Summary
This study details two cases of sulbactam/ampicillin (SBT/ABPC)-induced pneumonitis, a rare adverse reaction to this antibiotic combination. The findings suggest SBT/ABPC may cause lung inflammation, highlighting the need for vigilance in respiratory infection treatment.
Area of Science:
- Pulmonology
- Pharmacology
- Infectious Diseases
Background:
- Sulbactam/ampicillin (SBT/ABPC) is frequently used for respiratory tract infections.
- Drug-induced pneumonitis is an emerging concern with rising incidence.
- Accurate diagnosis of drug-induced lung injury is crucial for patient management.
Observation:
- Two patients developed pneumonitis after initiating SBT/ABPC therapy for respiratory infections.
- Radiographic evidence showed pulmonary infiltrates and shadows.
- Bronchoalveolar lavage fluid analysis revealed eosinophilia and lymphocytosis.
Findings:
- Lymphocyte stimulation tests confirmed SBT/ABPC as the causative agent in both patients.
- Discontinuation of SBT/ABPC and initiation of corticosteroid therapy led to symptom resolution.
- The CD4/CD8 ratio in bronchoalveolar lavage fluid increased, challenging previous diagnostic assumptions.
Implications:
- This is the first report of sulbactam/ampicillin-induced pneumonitis.
- The CD4/CD8 ratio may not be a reliable biomarker for diagnosing drug-induced pneumonitis.
- Increased awareness and diagnostic vigilance for SBT/ABPC-induced pneumonitis are warranted.